Browsing by Subject "Genetics of the nervous system"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
    (Springer Nature, 2022) Jiang, Yuanbing; Zhou, Xiaopu; Wong, Hiu Yi; Ouyang, Li; Ip, Fanny C. F.; Chau, Vicky M. N.; Lau, Shun-Fat; Wu, Wei; Wong, Daniel Y. K.; Seo, Heukjin; Fu, Wing-Yu; Lai, Nicole C. H.; Chen, Yuewen; Chen, Yu; Tong, Estella P. S.; Alzheimer’s Disease Neuroimaging Initiative; Mok, Vincent C. T.; Kwok, Timothy C. Y.; Mok, Kin Y.; Shoai, Maryam; Lehallier, Benoit; Morán Losada, Patricia; O'Brien, Eleanor; Porter, Tenielle; Laws, Simon M.; Hardy, John; Wyss-Coray, Tony; Masters, Colin L.; Fu, Amy K. Y.; Ip, Nancy Y.; Radiology and Imaging Sciences, School of Medicine
    Changes in the levels of circulating proteins are associated with Alzheimer's disease (AD), whereas their pathogenic roles in AD are unclear. Here, we identified soluble ST2 (sST2), a decoy receptor of interleukin-33-ST2 signaling, as a new disease-causing factor in AD. Increased circulating sST2 level is associated with more severe pathological changes in female individuals with AD. Genome-wide association analysis and CRISPR-Cas9 genome editing identified rs1921622 , a genetic variant in an enhancer element of IL1RL1, which downregulates gene and protein levels of sST2. Mendelian randomization analysis using genetic variants, including rs1921622 , demonstrated that decreased sST2 levels lower AD risk and related endophenotypes in females carrying the Apolipoprotein E (APOE)-ε4 genotype; the association is stronger in Chinese than in European-descent populations. Human and mouse transcriptome and immunohistochemical studies showed that rs1921622 /sST2 regulates amyloid-beta (Aβ) pathology through the modulation of microglial activation and Aβ clearance. These findings demonstrate how sST2 level is modulated by a genetic variation and plays a disease-causing role in females with AD.
  • Thumbnail Image
    Item
    Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers
    (Springer Nature, 2023-04-21) Brase, Logan; You, Shih-Feng; D'Oliveira Albanus, Ricardo; Del-Aguila, Jorge L.; Dai, Yaoyi; Novotny, Brenna C.; Soriano-Tarraga, Carolina; Dykstra, Taitea; Fernandez, Maria Victoria; Budde, John P.; Bergmann, Kristy; Morris, John C.; Bateman, Randall J.; Perrin, Richard J.; McDade, Eric; Xiong, Chengjie; Goate, Alison M.; Farlow, Martin; Dominantly Inherited Alzheimer Network (DIAN); Sutherland, Greg T.; Kipnis, Jonathan; Karch, Celeste M.; Benitez, Bruno A.; Harari, Oscar; Neurology, School of Medicine
    Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation. However, the cell-specific effect of variants in these genes is not fully understood. Here, we perform single-nucleus RNA-sequencing (snRNA-seq) on nearly 300,000 nuclei from the parietal cortex of AD autosomal dominant (APP and PSEN1) and risk-modifying variant (APOE, TREM2 and MS4A) carriers. Within individual cell types, we capture genes commonly dysregulated across variant groups. However, specific transcriptional states are more prevalent within variant carriers. TREM2 oligodendrocytes show a dysregulated autophagy-lysosomal pathway, MS4A microglia have dysregulated complement cascade genes, and APOEε4 inhibitory neurons display signs of ferroptosis. All cell types have enriched states in autosomal dominant carriers. We leverage differential expression and single-nucleus ATAC-seq to map GWAS signals to effector cell types including the NCK2 signal to neurons in addition to the initially proposed microglia. Overall, our results provide insights into the transcriptional diversity resulting from AD genetic architecture and cellular heterogeneity. The data can be explored on the online browser (http://web.hararilab.org/SNARE/).